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5ABSTRACT
The High Mobility Group A (HMGA) nonhistone chromatin proteins alter
chromatin structure and, thereby, regulate the transcription of several genes by either
enhancing or suppressing transcription factors. This protein family is implicated,
through different mechanisms, in both benign and malignant neoplasias.
Rearrangements of HMGA genes are a feature of most benign human mesenchymal
tumors. Conversely, unrearranged HMGA overexpression is a feature of malignant
tumors and is also causally related to neoplastic cell transformation. Recently, we
have generated transgenic mice carrying wild type or truncated HMGA genes under
transcriptional control of the cytomegalovirus promoter. These mice developed
pituitary adenomas secreting prolactin and growth hormone. We have recently
demonstrated that the mechanism of the HMGA2 induced-pituitary tumorigenesis is
based on the increased E2F1 activity.
To identify other genes involved in the process of pituitary tumorigenesis induced
by the HMGA2 and HMGA1 genes, we have analysed here the gene expression profile
of HMGA2- and HMGA1-induced pituitary adenomas in comparison with a pool of
ten normal pituitary glands from control mice using the Affymetrix MG MU11K
oligonucleotide array representing ~ 13,000 unique genes. We have identified 82
transcripts increased and 72 transcripts decreased of at least 4-fold in all mice
pituitary adenomas analyzed compared to normal pituitary gland. The microarray
results have been confirmed by semi-quantitative RT-PCR on RNA extracted from
different HMGA2- and HMGA1-induced mouse pituitary adenomas.
Then, we focused our attention on the Mia/Cd-rap and Cyclin B2 gene, the first
down-regulated and the second up-regulated in all pituitary adenomas tested by the
microarray. We demonstrated that the HMGA proteins directly bind and regulate their
promoters.
61. INTRODUCTION
1.1 HMG proteins
In the mammalian species the high-mobility-group HMG proteins have been
grouped in three distinct families: HMGB, HMGN, and HMGA.
These HMG families have been grouped based on similarity in physical and
chemical properties but they all act as architectural elements that affect multiple
DNA-dependent processes in the context of chromatin. In the nucleus, all HMG
proteins are highly mobile, bind transiently to chromatin and compete with histone H1
for nucleosome binding sites (Catez et al. 2004). However, each family is clearly
unique, has a characteristic functional motif, induces specific changes in their binding
sites, and performs unique cellular functions. It is now clear that HMGs impart
structural and functional plasticity to the chromatin fiber; however, their biological
function seems complex and their effects on the cellular phenotype are still not fully
understood.
The HMGB (formerly HMG1/2), chromosomal proteins, are characterized by the
HMG box, a DNA-binding domain that both introduces a tight bend into DNA and
binds preferentially to a variety of distorted DNA structures. The HMGB proteins
seem to act primarily as architectural facilitators in the formation of nucleoprotein
complexes; for example, in the assembly of complexes involved in recombination and
transcription. Recent genetic and biochemical evidences suggest that these proteins
can facilitate nucleosome remodeling. One mechanism by which HMGB proteins
could prime the nucleosome for migration is to loosen the wrapped DNA and so
enhance accessibility to chromatin-remodeling complexes and possibly also to
transcription factors. By constraining a tight loop of untwisted DNA at the edge of a
nucleosome, an HMGB protein could induce movements in the contacts between
certain core histones that would result in an overall change in nucleosome structure
(Bianchi et al. 2000, Thomas et al. 2001).
The HMGN (formerly HMG14/-17) proteins alter chromatin architecture by
decompacting the nucleosomal array. Studies on mini chromosomes have revealed
that two HMGN molecules bind to each nucleosome via their highly conserved
nucleosome-binding domains (Bustin 2001). The negatively charged C-terminal
domains induce chromatin unfolding such that the mini chromosomes have a
decreased sedimentation rate in a sucrose gradient and are more accessible to
nucleases. The functional consequences of this change in architecture are increases in
the rates of transcription and replication (Trieschmann et al. 1995; Crippa et al. 1993;
Vestner et al. 1998). Functional links between HMGN proteins and transcription have
also been suggested by studies on intact cells. In fact, various reports have shown that
HMGNs may be preferentially associated with actively transcribed genes (Bustin
72001), and intracellular localization experiments have shown that HMGNs colocalize
with nascent transcripts (Hock et al. 1998).
The HMGA proteins interact with a wide range of nuclear components including
transcription factors, components of the splicing machinery, proteins involved in
replication and chromatin assembly factors. HMGA proteins are easily detectable in
cells of early embryos and in undifferentiated or proliferating cells. In fully
differentiated cells their expression is sharply down-regulated except in malignant and
benign tumours (Fedele et al. 2001).
The wide range of cellular activities affected by HMG proteins supports the general
notion that these proteins act as structural components of chromatin but at the same
time raises the question as to which of the various cellular functions are most affected
by these proteins. Indeed, numerous studies suggest that HMG proteins also act as
specific cofactors in distinct cellular pathways. For example HMGA1 facilitates the
formation of an enhanceosome on the promoter of the interferon–β gene (Merika &
Thanos 2001), HMGB1 stabilizes the binding of the glucocorticoid receptor to
chromatin (Bianchi & Agresti 2005), and HMGN1 is specifically recruited by
Cockayne syndrome protein A to the polymerase stalled at UV-damaged DNA sites
(Fousteri et al. 2006).
1.2 HMGA family
HMGA protein family consists of HMGA1 and HMGA2 genes that encode four
proteins named HMGA1a, HMGA1b, HMGA1c and HMGA2, being the first three
proteins spliced forms of the HMGA1 gene. HMGA1 is located at chromosomal locus
6p21 in humans and in the t-complex locus on chromosome 17 in mice whereas
HMGA2 is located at chromosomal locus 12q14-15 in humans and at the pygmy locus
on chromosome 10 in mice.
The HMGA1a, HMGA1b and HMGA2 proteins are composed of 107, 96 and 108
amino acid residues, respectively. Each protein contains three basic domains, named
AT-hooks and an acidic C-terminal region (Fig. 1.1). The HMGA1a protein differs
from HMGA1b in that it has an additional insertion of 11 amino acid residues
between the first and the second AT-hook domains. The structure of HMGA2 protein
is very similar to that of HMGA1a/b; however, the first 25 amino acid residues are
totally different. Moreover, in HMGA2 there is a short peptide of 12 amino acid
residues between the third AT-hook and the C-terminal acidic tail (Fedele et al. 2001).
8Figure 1.1: Primary structure of human HMGA proteins. (A) Amino acid residues sequences
of HMGA1a, HMGA1b, and HMGA2 proteins. AT-hooks (AT) are evidenced in yellow, the C-
terminus in red. (B) Scheme of the sequences of HMGA proteins pointing out to the differently
spaced AT-hooks (in yellow) and C-terminal ends (in red) along the three protein molecules.
These proteins are very well conserved during evolution, and only a few differences
can be detected between the human and the murine HMGA sequences. HMGA1c has
a deletion of 67 nucleotides compared with the HMGA1a sequence. This deletion
results in a frameshift so that the two proteins are identical in their first 65 amino
acids and differ thereafter. Little is known about this form that, however, appears to
be the only isoform present in normal human and mouse testis (Fedele et al. 2001).
1.3 Physical and biochemical properties of the HMGA proteins
Originally the HMGA proteins were characterized by their small sizes (10,6-12
kDa), their solubility in dilute (5%) acids, their unusually high concentration of basic,
acidic and proline aminoacid residues, their highly phosphorylated state in vivo and
their rapid mobility during electrophoretic separations. Subsequently, HMGA proteins
were shown to bind to the minor groove of short stretches of AT-rich DNA. Given
these DNA-binding properties, it was somewhat surprising when biophysical
techniques indicated that the HMGA proteins, as free molecules, have very little, if
any, secondary structure. HMGA1a protein has relatively little α-helix or β-sheet
content and exhibits greater that 70% random coil or other structural characteristics
when free in solution. Nevertheless, when specifically bound to other molecules, such
as DNA or protein substrates, the HMGA proteins assume induced structural features.
For example, the DNA-binding regions of the HMGA proteins assume a planar,
crescent-shaped configuration called the “AT-hook” when specifically bound to the
9minor groove of short stretches of AT-rich DNA. Each HMGA protein has three
similar, but independent, AT-hook peptides with the consensus sequence of Pro-Arg-
Gly-Arg-Pro (with R-G-R-P being variant) flanked on either side by a number of
positively charged lysine/arginine residues. The core of the AT-hook motif is highly
conserved in evolution from bacteria to humans and is found in one or more copies in
a large number of other, non-HMGA proteins, many of which are transcription factors
or components of chromatin remodeling complexes (Reeves 2001).
HMGA binding can induce structural changes in bound DNA substrates. Depending
on the sequence, the organization, the topology or the length of the substrate itself,
HMGA binding can bend, straighten, unwind and induce looping in linear DNA
molecules. They are also able to introduce supercoils into relaxed plasmid DNAs in
vitro and induce localized changes in the rotational setting of DNA on the surface of
isolated nucleosome core particles. Interestingly, HMGA proteins also participate in
protein-protein interactions and induce structural changes in the bound protein
substrates. One of HMGA partners is PU.1, a member of the Ets transcription factor
family and an important regulator of the immunoglobulin heavy chain mu (IgGµ)
enhancer in B-lymphocytes. There is evidence suggesting that the interaction of PU.1
with HMGA1a induces a structural change in the PU.1 protein that increases its mu
enhancer binding affinity, resulting in an up-regulation of IgGµ gene transcription
(Lewis et al. 2001). Although the molecular mechanisms that mediate such induced
structural changes in bound proteins are unknown, as with DNA substrates, they are
likely to revolve around the intrinsic disorder and flexibility of the HMGA proteins
(Reeves 2001).
In addition to their other distinguishing characteristics, the HMGA proteins are
among the most extensively modified proteins found in the mammalian nucleus. A
variety of techniques have been employed to demonstrate that the HMGA proteins are
subject to in vivo post-synthetic phosphorylation, acetylation, methylation and poly-
ADP-ribosylation reactions. These secondary biochemical modifications are dynamic,
rapidly responding to both intra- and extracellular signaling events, and markedly
influence both the substrate-binding properties of the HMGA proteins and their
biological activities.  HMGA proteins undergo phosphorylation by various protein
kinases, including protein kinase C (PKC), cdc2 and casein kinase II. A link between
apoptosis induced in leukaemic cells and the degree of phosphorylation of HMGA1a
protein has been described (Diana et al. 2001). At the early stages of the apoptotic
process, the HMGA1a protein is hyper-phosphorylated. Subsequently, when the
apoptotic bodies are formed, the HMGA protein becomes almost completely de-
phosphorylated.
HMGA proteins are also regulated by acetylation. The transcriptional coactivator
CBP/p300 (CREB-binding protein) and P/CAF (CBP-associated cofactor) acetylate
HMGA1a at distinct lysine residues, causing distinct effects on transcription.  In the
context of the human ß-interferon gene expression, acetylation of HMGA1a by both
CBP and P/CAP is required for the enhanceosome activation, whereas only CBP
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acetyltransferase activity is required for enhanceosome destabilization and post-
induction turn-off (Munshi et al. 1998).
HMGA proteins have the ability to physically interact with a large number of
proteins, most of which are transcription factors: AP-1, ATF-2/c Jun heterodimer,
IRF-1, c-Jun, NF-kB p50/p65 heterodimer, C/EBPß, Elf-1, NF-AT, NF-kB p50
homodimer, NF-kB p65, NF-Y, Oct-1, Oct-2A, PIAS3, PU.1 RNF4, HIPK2, SRF and
Tst-1/Oct-6. Recently, other molecular partners have been discovered using a
proteomic approach (Table 1), suggesting an involvement of HMGA proteins in other
chromatin functions, such as RNA-processing, DNA replication, chromatin structural
organization and remodeling. (Sgarra et al. 2005, Pierantoni et al. 2006).
Table 1   HMGA molecular partners identified by MS analysis
Protein name Accesion number
CBF-beta Q13951
SF3a120 Q15459
hnRNP K Q07244
hnRNP H P31943
hnRNP F P52597
hnRNP MP52272
Ku80 P13010
RBBP-4 Q09028
RBBP-7 Q16576
RuvB-like 2 Q9Y230
Tubulin alpha-1 chain P05209.
Tubulin beta-1 chain P07437
CapZ alpha-1 P52907
NPM P06748
Heat shock cognate 71 kDa protein P11142
GRP 78 P11021
GRWD Q9BQ67
REC14 Q9GZS3
ATP-dependent helicase (DDX1 Q92499
hnRNP M P52272
TAFII68 Q92804
DDX17 Q92841
DDX5 P17844
Heat shock cognate 71 kDa Protein P11142
RNA-binding protein FUS P35637
DRP-2 Q16555
Tubulin beta-1 chain P07437
MA32 Q07021
hnRNP H3 P31942
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1.4  HMGA proteins and gene transcription
Until 2004 there were reports of over 50 different eukaryotic and viral genes whose
transcriptional expression was regulated by HMGA proteins in vivo (Table 2). The
vast majority (>35) of these are positively regulated and their inducible expression is
controlled by a variety of biological and environmental stimuli.
The promoter regions of many of the positively regulated genes contain multiple
stretches of AT-rich sequence. Transcriptional activation of these type of promoters
often involves the formation of an “enhanceosome”, a stereo-specific, multi-protein
complex that includes HMGA proteins and other transcription factors making specific
protein-DNA and protein-protein contacts in intricate, but precise, ways. In the case
where HMGA proteins act as negative regulators of gene transcription they often
serve as inhibitors of enhanceosome formation, usually by sterically blocking the
functional binding of other crucial transcription factors to their recognition sites in
gene promoters (Reeves 2001).
One of the best-studied mechanisms of gene regulation in which HMGA proteins
are involved is that of the interferon-β gene (IFN-β). The activation of the IFN-β
expression is due to a multifactor complex, that assembles in the nucleosome-free
enhancer region of the gene, formed by the factors NF-kB, IRF, ATF2/cJun, and the
HMGA1a protein (Fig. 1.2). HMGA1a plays a double function in this context: (i)
induces allosteric changes in the DNA, thus increasing the affinity of the transcription
factors for their binding sites and (ii) establishes protein-protein interactions with the
same factors. This structure, called enhanceosome, is responsible for the modification
and the remodeling of a nucleosome that masks the TATA-box; consequently,
transcription can start. This remodeling is triggered by the recruitment through the
“enhanceosome” of GCN5/PCAF that acetylates the nucleosome and also HMGA1a
at K64, the latter modification resulting in the stabilization of the enhanceosome
itself. Later, another acetyltransferase, called CBP, acetylates HMGA1a at K70
destabilizing the enhanceosome and, consequently, repressing transcription (Munshi
et al. 1998).
Figure 1.2  HMGA proteins facilitate the assembly of specific multiprotein complexes
required for gene promoter activation: example of the human β−interferon gene.
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Table 2   Genes Regulated by HMGA Proteins
Positive Regulation Negative Regulation
Vascular Endothelial Tissue CD44 β-Globin
E-Selectin IL-4
IGFBP-1 IgE
iNOS GP 91-phox
COX-2 TCRα
SM22α BRCA1
Immune System MGSA/GROα RAG2
CXCL1
IFN-β
GM-CSF
TNF-β 
IL-2
IL-2Rα
IL-15
HLA-II
c-fos
IgG Heavy Chain
Viral Genes HIV-1 LTR
HSV-1 IE-3
HSV-1 EBNA1
BV EBNA1
VHP 18
JV virus Early & Late Genes
Other Leptin
GATA-1
Hum Insulin Receptor
α-ENaC
Tyrosinase
Rhodopsin
Neurogranin IRC3
PKCγ
mRANTES
Plant Genes Plastocyanin
Nodulin N23 gene
Ferredoxin
Phytochrome A3
Glutamine Synthetase
Soybean hsp17.5E
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1.5 HMGA functions in development
The high expression of HMGA proteins during embryogenesis suggests that they
play important roles in development. Indeed, the phenotype characterization of mice
knockout for each of the HMGA genes revealed crucial roles of these proteins in
different aspects of development. Cardiac hypertrophy and type 2 diabetes were
observed in Hmga1-null and heterozygous mice (Fedele et al. 2006a, Foti et al. 2005)
suggesting that quantitatively appropriate expression of the HMGA1 proteins are
required for cardiomyocytic cell growth and function of the insulin pathway. Hmga2-
null and heterozygous mice showed a pygmy phenotype with a decreased body size of
20% in heterozygous and 60% in homozygous mice, and a drastic reduction of the fat
tissue (Zhou et al. 1995), suggesting a critical role of the Hmga2 gene in the control of
the body growth and adipocyte proliferation and differentiation.
We have previously shown that HMGA1 is present in mitotic cells (spermatogonia
and primary spermatocytes), whereas HMGA2 is highly expressed in meiotic and
post-meiotic cells (secondary spermatocytes and spermatids) (Chieffi et al. 2002, Di
Agostino et al. 2004); in addition, we have demonstrated a specific function for
HMGA2 in the regulation of spermatogenesis, because this differentiation program is
dramatically hampered in HMGA2-/- mice in spite of the presence of HMGA1 (Chieffi
et al. 2002).
Therefore, even though HMGA1 and HMGA2 may have overlapping functions,
they seem to have different roles in development.
1.6  HMGA expression in normal and neoplastic tissues
The HMGA2 gene is not expressed in any of the several adult mouse and human
tissues tested. A very low expression has been only observed in CD34 positive
hematopoietic stem cells, and in mouse pre-adipocytic proliferating cells. The
HMGA1 gene is expressed at very low levels in adult murine and human tissues: a
higher expression was observed only in testis, skeletal muscle ant thymus.
Conversely, both the genes are widely expressed during embryogenesis.
Over-expression of the HMGA proteins was instead found to be a common feature
of experimental and human malignant neoplasias, including thyroid, prostate, uterus,
breast, colorectum, ovary and pancreas carcinomas (Fedele et al. 2001a). Recently, in
our laboratory, we have correlated HMGA1 expression with the histological grade of
human glial tumors (Donato et al. 2004). Moreover, the expression level of the
HMGA proteins is significantly correlated with parameters of poor prognosis in
patients with colorectal cancer (Chiappetta et al. 2001). In all of these
epithelial/endothelial cell-derived malignant tumors, the over-expressed proteins are
full-length non-mutants forms of the HMGA proteins. In contrast to the situation in
carcinomas, benign tumors of mesenchymal origin (lipomas, leiomyomas,
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fibroadenomas, aggressive myxomas, pulmonary hamartomas and endometrial
polyps) often contain chromosomal rearrangements that result in the creation of new
hybrid genes that code for chimeric proteins in which the AT-hooks of the HMGA
proteins are fused to ectopic peptidic sequences (Hess 1998).
1.7 HMGA as cellular oncogenes
Several studies, both in vitro and in vivo, clearly established the oncogenic potential
of HMGA proteins. Transfection of an antisense construct for the HMGA2 cDNA
into normal thyroid cells (FRTL5), followed by infection with transforming
myeloproliferative sarcoma virus or Kirsten murine sarcoma virus KiMSV, generated
cell lines that expressed significant levels of the retroviral transforming oncogenes v-
mos or v-ras-Ki and removed the dependency on thyroid-stimulating hormones.
However, in contrast with untransfected cells or cells transfected with the sense
construct, those containing the antisense construct did not demonstrate the appearance
of any malignant phenotypic markers (growth in soft agar and tumorigenicity in
athymic mice). HMGA1 protein was also reduced by HMGA2 antisense, suggesting
HMGA1 also might play a role in neoplastic transformation (Berlingieri et al. 1995).
Also the block of HMGA1 protein expression prevented thyroid cell transformation
by KiMSV (Berlingieri et al. 2002), thus strongly indicating that HMGA1 protein
plays a crucial role and HMGA2 an accessory role in thyroid cell transformation.
Consistent with these data, the expression of an adenovirus carrying the HMGA1 gene
in an antisense orientation  suppressed HMGA1 protein synthesis and induced cell
death of two human thyroid anaplastic carcinoma cell lines, but not normal thyroid
cells (Scala et al. 2000). Nevertheless, it is noteworthy that HMGA1 alone does not
transform normal rat thyroid cells PC Cl3: the transfected cells entered the S phase
earlier than normal cells, they stopped replicating at G2-M phase and underwent
programmed cell death (Fedele et al. 2001b). The different cellular context may
account for the different effects of HMGA1 overexpression.
More direct evidence of the role of HMGA proteins in malignant transformation
came from work by Wood et al. (Wood et al. 2000). They showed that increased
expression of HMGA1 and HMGA2 leads to the neoplastic transformation of Rat 1a
and CB33 cells, and induce distant metastasis when these cells are injected into
athymic mice. Moreover, human breast epithelial cells harboring a tetracycline-
regulated HMGA1 transgene form both primary and metastatic tumors in nude mice
only when the transgenes are actively expressed (Reeves et al. 2001). Interestingly,
the HMGA1b, rather than the HMGA1a isoform, appears the most effective elicitor of
both neoplastic transformation and metastatic progression in vivo (Reeves et al. 2001).
Furthermore, expression of either antisense or dominant-negative HMGA1 constructs
inhibits both the rate of proliferation of tumor cells and their ability to grow
anchorage-independently in soft agar (Reeves et al. 2001).
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The generation of transgenic mice overexpressing either the HMGA1 or the HMGA2
gene confirmed their oncogenicity in vivo. In fact, both the HMGA1 and HMGA2
transgenic mice develop GH/PRL-secreting pituitary adenomas and T/NK lymphomas
(Fedele et al. 2005, Baldassarre et al. 2001, Fedele et al. 2002).
Besides the obvious role of HMGA in oncogenesis as oncogenes, an antioncogenic
potential was recently attributed to HMGA1 proteins. In fact, antiproliferative
activities were observed in lymphoproliferative disorders (Fedele et al. 2006a) and
during cellular senescence (Narita et al. 2006), which prevent rather than promote
malignant transformation. In the context of cellular senescence, HMGAs modulate
global chromatin architecture by contributing to the formation of senescence-
associated heterochromatin foci.
1.8 Role of HMGA proteins in neoplastic transformation
Several mechanisms have been proposed to account for the transforming ability of
the HMGA proteins. According to their main function of regulating gene
transcription, most of these mechanisms are based on the ability of the HMGA
proteins to down- or up-regulate the expression of genes that have a critical role in the
control of cell proliferation and invasion (Sgarra et al. 2004, Martinez-Hoyos et al.
2004, Fedele et al. 2005). Recently described interacting partners, such as nuclear
factor (NF)-_B (Merika and Thanos 2001) and the tumor suppressors p53 (Frasca et
al. 2006, Pierantoni et al. 2006) or pRB (Fedele et al. 2006b), provide a clue to how
HMGA proteins could influence gene expression in cancer. However, HMGA
proteins also inhibit nucleotide excision repair (Reeves and Adair 2005, Adair et al.
2005) and other DNA repair systems (Boo et al. 2005, Muller-Tidow et al. 2004),
which could mean that HMGA proteins promote tumorigenesis by increasing genome
instability.
1.9      HMGA in pituitary tumorigenesis
Recently, our group has shown HMGA2 gene amplification and overexpression in
human prolactinomas (Finelli et al. 2002). Consistently, trisomy of chromosome 12,
which harbors HMGA2, represents the most frequent cytogenetic alteration in human
prolactin-secreting pituitary adenomas, and structural rearrangements on chromosome
12 are recurrent in prolactinomas (Finelli et al. 2000).
HMGA2 overexpression was also found in 12 out of 18 Non Functional Pituitary
Adenomas (NFPA) but, in contrast to prolactinomas, HMGA2 upregulation was
associated with amplification and/or rearrangement of the HMGA2 locus in very few
cases (Pierantoni et al. 2005).
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In agreement with these results transgenic mice carrying the Hmga2 gene under the
transcriptional control of the cytomegalovirus promoter developed pituitary adenomas
secreting GH and prolactin (Fig. 1.3), suggesting a crucial role for HMGA2 in
pituitary tumorigenesis. Interestingly, the same phenotype is also observed in mice
overexpressing Hmga1 (Fedele et al. 2005) indicating that both HMGA family genes
could play a pivotal role in pituitary adenoma development. However, neither
rearrangements nor amplification of the HMGA1 locus has been detected in human
pituitary adenomas. More recently it has been reported that HMGA2 induces pituitary
adenomas in Hmga2-transgenic mice by binding to pRB and enhancing E2F1 activity
(Fedele et al. 2006b). The mechanism by which it occurs is unique, since although
HMGA2 binds to the pRB A/B pocket domain, it does not compete with the E2F1
protein, unlike proteins encoded by viral oncogenes such those produced by the E1A
adenovirus. Rather, HMGA2 displaces histone deacetylase 1 (HDAC1) from the
pRB/E2F1 complex, resulting in enhanced acetylation of both E2F1 and DNA-
associated histones, thereby promoting E2F1 activation (Fig. 1.4). The crucial role of
HMGA2-mediated E2F1 activation in pituitary tumorigenesis was confirmed by
crossing Hmga2-overexpressing with E2f1-knockout mice, which resulted in the
suppression of pituitary tumorigenesis in double mutant mice. Although the E2F1
activation might represent the major point for the generation of pituitary adenomas in
transgenic mice, we cannot exclude that other complementary mechanisms may be
envisaged for the role of HMGA2 in pituitary tumorigenesis. In fact, also in the E2F1
minus background, the HMGA2 mice develop a certain number of pituitary
neoplasias, even though with a lower frequency and a minor phenotype.
                                               
Figure 1.3 MRI analysis of a female transgenic mouse 11 months old (right) compared to a
wild type control mouse (left). The arrow indicates a large tumor mass in the skull base.
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Fig. 1.4 Model of E2F1 activation by HMGA2 protein. HMGA2 protein activates E2F1
transcriptional activity, displacing HDAC1 from pRB/E2F1 complex.
1.10 Human pituitary tumors
Pituitary tumors represent 10-15% of intracranial neoplasms (Kovacs e Horvath
1986, Monson 2000), are infrequent in childhood (Mukai et al. 1986; Kane et al.
1994) and are more common in females (Kane et al. 1994).
Pituitary adenomas have been classified by various groups of investigators in
different ways. A functional classification of pituitary adenomas defines these tumors
based on their hormonal activity in vivo. This is the common clinical approach used
by endocrinologists. It characterizes the tumors as GH producing adenomas
associated with acromegaly and/or gigantism, adenomas causing hyperprolactinemia
and its clinical sequela, ACTH-producing adenomas associated with Cushing’s or
Nelson’s syndromes, TSH-producing tumors, the rare clinically detectable
gonadotroph adenomas, and the large group of clinically nonfunctioning or
“endocrinologically inactive” adenomas.
Molecular genetics studies have demonstrated that these tumors are monoclonal in
origin (Hervan et al. 1990) indicating that an intrinsic defect in a single pituitary cell
is the primary event in pituitary tumor. A multistep theory of carcinogenesis,
involving changes in gene expression as well as hormone or growth factor
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stimulation, has been implicated in their pathogenesis. Several studies have examined
human pituitary tumors for genetic abnormalities in a number of known oncogenes
and tumor suppressor genes, but have revealed limited information on the molecular
events underlying their pathogenesis.
Pituitary oncogenes gsp, ccnd1 and PTTG are abundant in a significant number of
cases (Yu and Melmed 2001). The gsp oncogene is predominantly found in a subset
of GH-secreting tumors and results from a mutated, constitutively active α subunit of
the heterodimeric Gs protein (Landis et al. 1990). Mutation in the ras, p53 and Braf
genes are also not common in human pituitary tumors (Karga et al. 1992; Herman et
al. 1993, De Martino et al. 2007).
Alterations of the genes involved in the cell cycle seem to have a critical role in the
onset of pituitary neoplasias. The loss of Rb and p27Kip1 genes has been demonstrated
as a cause of murine pituitary adenomas. In fact mice deficient in p27 (Nakayama et
al. 1996) or with heterozygous Rb mutations develop pituitary tumors (Hu et al.
1994). However, the role of this tumor suppressor genes for human pituitary
adenomas remains elusive (Tanaka et al. 1997).
Potential candidates for the suppressor genes are now emerging. The recently cloned
multiple endocrine neoplasia type I gene is one example (Chandrasekharappa et al.
1997). MEN1A mutations, constantly found in patients affected by the MEN-1
syndrome, which includes pituitary adenomas, have never been found in sporadic
pituitary adenomas (Asa et al. 1998).
Alterations of c-myc/bcl-2, and ras, although rare, appear to be an important cause
of the process by which adenoma cells acquire aggressive phenotypes (Wang et al.
1996, Karga et al. 1992). Point mutations of ras oncogene were found in a highly
aggressive prolactinoma and in metastatic pituitary carcinomas, but not in the
majority of functioning and nonfunctioning pituitary tumors (Pei et al. 1994).
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Aim of the work
The HMGA overexpression in many neoplastic diseases leads us to generate HMGA
transgenic mice. High incidence of growth hormone/prolactin secreting pituitary
adenomas developed from these transgenic mice demonstrated a crucial role for
HMGA2 in the pathogenesis of this tumor according with the findings in human
prolactinomas where HMGA2 is amplified and overexpressed. The main mechanism
by which HMGA2 appears involved in pituitary tumorigensis is through E2F1
activation (Fedele et al. 2006b). Nevertheless, it is not the only one since HMGA2
transgenic mice deficient for E2F1 still develop pituitary neoplasias, even though with
a minor incidence and a milder phenotype (Fedele et al. 2006b).
Therefore, the aim of the present work has been to find out other molecular changes
that might contribute to the development of the HMGA-induced pituitary tumors. For
this reason, using the oligonucleotide microarray hybridization technique, we first
analysed the expression profile of three pituitary adenomas developed by HMGA
transgenic mice in comparison with a pool of normal pituitary glands from wild-type
animals. In this way we could identify the genes that are regulated, positively or
negatively, by HMGA proteins in pituitary tumors.
Subsequently, we focused on two of the genes identified, Mia/Cd-rap and Cyclin
B2, being the first a secreted product of malignant melanoma cells (Blesch et al.
1994), and the other an important cell cycle gene. We investigated if HMGA proteins
were able to bind to the promoters of these genes, both in vitro and in vivo, and to
directly regulate their transcription. Moreover, since a direct role of Mia/Cd-rap in
pituitary tumorigenesis has been not identified so far, we analyzed its potential to
influence pituitary adenoma cells proliferation.
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2. Materials and methods
2.1 Microarray Analysis
The Affymetrix standard protocol has been described extensively elsewhere
(Affymetrix GeneChip®).
Briefly, cRNA was prepared from 8 µg of total RNA, hybridized to MG MU11K
Affymetrix oligonucleotide arrays (containing about 13000 murine transcripts),
scanned, and analyzed according to Affymetrix (Santa Clara, CA) protocols. Scanned
image files were visually inspected for artifacts and normalized by using GENECHIP
3.3 software (Affymetrix). The individual gene expression levels for each of the three
pituitary adenomas arrays were divided by the expression level in the normal pituitary
tissue. Thus, the data are presented as relative to the expression in normal pituitary
tissue. The fold-change values, indicating the relative change in the expression levels
between mutated and wild-type samples, were used to identify genes differentially
expressed between these conditions
2.2 Cell cultures and transfection
All cell lines, except for aT3-1 (kindly provided by Dr P. Mellon, University of
California, San Diego, CA, USA) were purchased from ATCC. They were all cultured
in DMEM containing 10% fetal bovine serum (HyClone, Logan, UT) and 50 µg/ml
gentamicin (Life Technologies, Inc., Grand Island, NY) in a humidified atmosphere of
95% air and 5% CO2. B16F0 are murine melanoma cells; AtT20 and aT3-1 are
murine pituitary adenoma cells secreting ACTH and gonadotoph hormones,
respectively; RC-4B/C are rat pituitary adenoma cells secreting GH, FSH, LH, GnRH,
ACTH and TSHb; GH1, GH3 and GH4c1 are rat pituitary adenoma cells secreting
prolactin and growth hormone.
Transfection were carried out by using Lipofectamine 2000, according with to
manufacturer’s instructions. Transfection efficiencies were normalized by using
Renilla luciferase expression assayed with the dual luciferase system (Promega). All
the assays were performed in triplicate and repeated in three independent experiments.
2.3 Plasmids
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The 5’ flanking region of the mouse Mia/Cd-rap gene spanning nucleic acid
residues -1396 to -1 with respect to the ATG protein start codon was amplified by
PCR and inserted into the promoterless luciferase plasmid pGL3-basic (Promega) to
obtain the MIA-luc pGL3 plasmid. The human Mia/Cd-Rap expression plasmid,
pCMV6-XL4/Mia was commercially available (TC116021 - OriGene Technologies,
Rockville, MD). pBABE-puro was already described (Monaco et al. 2001).
The plasmid of B2-luci has been supplied gently by Dr. G. Piaggio from Rome
(Manni et al.2001).
2.4 Luciferase and Colony Assays
For the Luciferase assay, a total of  2 x 105 B16F0 cells (or NIH3T3) were seeded
into each well of six well plate and transiently transfected with 1 µg of MIA-luc pGL3
(or with CycB2-luc) and with the indicate amounts of pCEFLHa-HMGA1 (Melillo et
al. 2001) and pCEFLHa-HMGA2 (Fedele et al. 2006b), together with 0.5 µg of
Renilla and various amounts of the pCEFLHa plasmid to keep the total DNA
concentration constant. Transfection efficiencies were normalized by using Renilla
luciferase expression assayed with the dual luciferase system (Promega). All
tranfection experiments were repeated at least three times.
For the colony assay, GH3 and GH4 cells were seeded at a density of 2.5 x 106 per
10-mm dish. Two days after, cells were transfected with 10µg of pCMV6-XL4 plus 2
µg of pBabe-puro or 10µg of pCMV6-XL4/Mia plus 2µg of pBabe-puro. After about
15 days, cells were stained with 500 mg/ml of crystal violet in 20% methanol, and the
resulting colonies were counted.
2.5 RNA Extraction
Tissues were snap-frozen in liquid nitrogen and stored at –80°C until use. Total
RNAs were extracted from tissues and cell culture using TRI REAGENT (Molecular
Research Center, Inc.) solution, according to the manufacturer’s instructions. The
integrity of the RNA was assessed by denaturing agarose gel electrophoresis (virtual
presence of sharp 28S and 18S bands) and spectrophotometry.
2.6 Cluster analysis by Multiexperiment viewer (MeV)
Microarray data have been elaborated by the Multiexperiment viewer (MeV) system
to get gene expression signature of the samples analysed. MeV is a system of cluster
analysis for genome wide expression data from DNA microarray hybridization, that
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uses standard statistical algorithms to arrange genes according to similarity in pattern
of gene expression. In our analysis we used a 4-fold difference in expression level
between normal and tumoral samples.
2.7 Semiquantitative and quantitative RT-PCR
RNAs were treated with DnaseI (Invitrogen) and reverse-transcribed using random
exonucleotides as primers and MuLV reverse transcriptase (Perkin Elmer). To ensure
that RNA samples were not contaminated with DNA, negative controls were obtained
by performing the PCR on samples that were not reversed-transcribed but otherwise
identically processed. For semiquantitative PCR, reactions were optimized for the
number of cycles to ensure product intensity within the linear phase of amplification.
The PCR products were separated on a 2% agarose gel, stained with ethidium
bromide and scanned using a Typhoon 9200 scanner. Digitized data were analyzed
using Imagequant (Molecular Dynamics). Quantitative PCR was performed with
SYBR® Green PCR Master Mix (Applied Biosystems) as follows: 95 °C 10 min and
40 cycles (95 °C 15 s and 60 °C 1 min). Each reaction was performed in duplicate. To
calculate the relative expression levels we used the 2-ΔΔCT method (Livak et al.
2001). The primers sequences are:
h-MIA Real time fw: 5’-TTTCCCCAGTAGCATTGTCC-3’
h-MIA Real time rev:5’-TCTGTCTTCACATCGACTTTGC-3’
h-CyclinB2 fw: 5’-AGCTATGATCCTGCCAGTGC-3’
h-CyclinB2 rev: 5’- CAGAATGCTGTGTTCAGGTTACA-3’
h-HMGA1 fw: 5’- AAAAGGACGGCACTGAGAAG-3’
h-HMGA1 rev: 5’- CTCTTAGGTGTTGGCACTTCG-3
2.8 Protein Extraction and Western blot
Tissues and cell culture were lysed in buffer 1% NP40, 1 mmol/L EDTA, 50
mmol/L Tris-HCl (pH 7.5), and 150 mmol/L NaCl, supplemented with complete
protease inhibitors mixture (Roche Diagnostic Corp.). Total proteins were separated
by SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad). Membranes
were blocked with 5% nonfat milk and incubated with antibody against MIA (A-20
Santa Cruz, sc-17047), or with antibody Cyclin B2 (N-20 Santa Cruz, sc-5235).
Bound antibody was detected by the appropriate secondary antibody and revealed
with an enhanced chemiluminescence system (Amersham-Pharmacia Biotech).
2.9 Electrophoretic Mobility-Shift Assay
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Protein/DNA-binding was determined by electrophoretic mobility shift assay
(EMSA), as previously described (Battista et al. 1995). Briefly, five to 20 ng of
recombinant protein were incubated in the presence of a 32P-end-labeled double
strande oligonucleotide (specific activity, 8,000–20,000 cpm/fmol). spanning from
base -1130 to -1100 of the mouse Mia/Cd-rap  promoter region (5'-
AAACCCTGAAATAAATCTTTTTTTCCCCTT-3'), or from -229 to –189 of the
m o u s e  C y c l i n  B 2   p r o m o t e r  r e g i o n  ( 5 ’ -
AGCAAATTGACAAGCAAATACAAGCCAGCCAATCAACGTG-3’).
The DNA-protein complexes were resolved on 6% non-denaturing acrylamide gels
and visualized by exposure to autoradiographic films.
2.10 Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was carried out with an acetyl-histone H3
imunoprecipitation assay kit (Upstate Biotechnology) according to the manufacture’s
instruction. Approximately 3 x 107 cells of the NIH3T3 cell line were grown on 75-
cm2 dishes and cross-linked by the addition of formaldehyde (to 1% final
concentration) to attached cells. Cross-linking was allowed to proceed at room
temperature for 5 minutes and was terminated with glycine (final concentration, 0.125
mol/L). Cells were collected and lysed in buffer containing 5 mmol/L PIPES (pH 8.0),
85 mmol/L KCl, 0.5% NP40, and protease inhibitors (1 mmol/L phenylmethylsulfonyl
fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin), on ice for 10 minutes. Nuclei were
pelleted by centrifugation at 5,000 rpm for 5 minutes at 4°C and resuspended in buffer
containing 50 mmol/L Tris-Cl (pH 8.1), 10 mmol/L EDTA, 1% SDS, the same
protease inhibitors, and incubated on ice for 10 minutes.
Chromatin was sonicated on ice to an average length of about 400 bp with a Branson
sonicator model 250. Samples were centrifuged at 14,000 rpm for 10 minutes at 4°C.
Chromatin was pre-cleared with protein A Sepharose (blocked previously with 1
mg/ml BSA) at 4°C for 2 hours. Pre-cleared chromatin of each sample was incubated
with 2 µg of antibody anti-HA (sc-7392, Santa Cruz Biotechnology) at 4°C overnight.
An aliquot of wild-type sample was incubated also with anti-IgG antibody. Next, 60
µl of a 50% slurry of blocked protein G Sepharose was added, and immune complexes
were recovered. The supernatants were saved as "input." Immunoprecipitates were
washed twice with 2 mmol/L EDTA, 50 mmol/L Tris-Cl (pH 8.0) buffer and 4 times
with 100 mmol/L Tris-Cl (pH 8.0), 500 mmol/L LiCl, 1% NP40, and 1% deoxycholic
acid buffer. The antibody-bound chromatin was eluted from the beads with 200 µl of
elution buffer (50 mmol/L NaHCO3, 1% SDS). Samples were incubated at 67°C for 5
hours in the presence of 10 µg RNase and NaCl to a final concentration of 0.3 mol/L
to reverse formaldehyde cross-links. Samples were then precipitated with ethanol at
–20°C overnight. Pellets were resuspended in 10 mmol/L Tris (pH 8)-1 mM EDTA
and treated with proteinase K to a final concentration of 0.5 mg/ml at 45°C for 1 hour.
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DNA was extracted with phenol/chloroform/isoamyl alcohol, ethanol-precipitated,
and resuspended in water.
Input DNA and immunoprecipitated DNAs were analyzed by PCR for the presence
of Mia/Cd-rap or Cyclin B2 promoters sequences. PCR reactions were performed with
AmpliTaq gold DNA polymerase (Perkin-Elmer). The primers used to amplify the
sequence of the promoters were:
--Mia /Cd- rap  5'-TTGCTGGTGCATGCCTTA-3’ (forward) and 5'-
TCTTAACCGCTGAGCCATCT-3' (reverse);
--Cyclin B2 5’- TAAGGATGATGGACCAAGAG (forward) and 5’-
CCCTCGACCTAAATTACACA -3’ (reverse).
PCR products were resolved on a 2% agarose gel, stained with ethidium bromide,
and scanned using a Typhoon 9200 scanner.
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3. Results and Discussion
3.1 Gene Expression Profile Analysis
RNAs were extracted from a pool of normal pituitary glands and from three pituitary
adenomas developed in four different HMGA transgenic mice (2 HMGA2, 1
HMGA1, 1 HMGA2/T), and were hybridized to the Affymetrix MG MU11K-A
oligonucleotide array, representing about 13,000 unique genes. The number of
transcripts increased or decreased in all pituitary adenomas versus normal gland is
shown in the Fig. 2.1. Of the 13.059 transcripts represented on the array, 1560 had a
1- to 3-fold, 290 had a 3- to 4-fold, 154 had a 4- to 10-fold, and 11 had a >10-fold
change. We examined the 154 transcripts that had a fold change ≥ 4 in all HMGA-
induced pituitary adenomas versus normal pituitary gland assuming that the genes
altered in their expression in tumors might represent candidate genes involved in
pituitary tumorigenesis.
Among these transcripts, 82 were increased and 72 were decreased, including 108
known genes, 30 expression sequence tags (ESTs) and 16 unknown genes. The
relative fold-changes of these genes, grouped according to their biological function
are shown in Table 1.
Figure 2.1  Gene expression profile of pituitary adenomas of HMGA transgenic mice
compared to normal pituitary gland. Transcripts are grouped according to fold change.
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A natural basis for organizing gene expression data is to group together genes with
similar patterns of expression. Using the Multiexperiment Viewer (MeV), a free Java
application which is used to compare datasets from microarray expression
experiments (Eisen et al. 1998), we clustered the gene expression profile of HMGA-
induced pituitary adenomas in comparison with normal gland. The results, illustrated
in Fig. 2.2, clearly show the similar pattern of expression of several genes in all
pituitary adenomas with respect to normal pituitary gland.
Table 1. Genes differentially expressed with a ≥ 4-fold change in HMGA-induced pituitary
adenomas versus normal pituitary gland.
__________________________________________________________________________________
Description         GenBank accession no FC 1 FC 2 FC 3 FC 4
Immune function
Thy-1 X03151 4.0 1.3 5 4
Ob/Ob haptoglobin M96827 10.2 2.2 1.2 2.3
MRP8 M83218 107 3.7 1.3 5.4
Clon B6 myeloid second. granule prot L37297 105.1 2.2 1.7 12
Interferon inducible protein 1-8U W12941 -2.25 -2.7 -3.3 -3.1
VCAM-1 X67783 32.6 3.7 4.1 9.8
Il-6 receptor X51975 -3.7 -2.6 -4.3 -5.1
Ig kappa chain (HyHEL-10) M35667 3.2 7.5 1.9 2.8
G protein  γ 3 subunit AA049022 -2.5 -1.5 -7.9 -3.8
GM-CSF X03019 -4-.1 -4.9 -5 -6.7
Myelopeptide-2 M23236 9.2 10.6 9.5 9.3
IFN-gamma AA015168 -7.5 -10.2 -13 -11.2
antigen pB7 M55561 5.5 -5.2 -5.6 -2.3
Cell proliferation
β-Enolase W33721 -1.5 -2.2 -1.3 -2.9
CAD protein AA466758 2.1 3 5.3 4.6
dUTPase AA110424 1.1 1.4 5.2 3.8
Galectin-3 W10936 14.3 8.2 6.3 10.1
Signal trasduction
PKCalpha M25811 2 1.8 6.6 3.2
FKBP65 binding protein L07063 6.3 8.3 12.2 9.7
mR-PTPµ X58287 2.7 2.8 4 5.7
GTP-binding protein Gb4 M63658 2.4 3.7 6.8 4.6
p36 D10024 -4 -4.4 -11 -7.7
AEBP1 X80478 -12.6 -3-3 -36.9 -15.1
AP-2 NM_011547 8.4 12.5 4.4 5.9
A-RAF AA060840 -11.5 -11-7 -12.2 -10.8
Vitronectin m77123 21.7 10.5 6.1 14.3
STEP61 U28217 -5.4 -9.9 -18.2 -15.9
Cell cycle
CycD3 AA266783 4.4 6.1 3.5 5.2
CycB2 X66032 5.6 8 6.1 7.9
CycB X58708 4.5 6.3 4.4 6.9
cdc2 U58633 4 11.2 3.6 9.8
GADD-45 l28177 -2.6 -5.9 -3.9 -6.1
Antigen
SSAV provirus pol gene C76668 2.1 1.6 5.1 4.3
(Emv-3) gag gene U63133 -1.1 -1.4 -2 -3.2
Mitocondrial proteins
Heme oxygenase M33203 30.5 3.2 2 12.2
Fosfadilserine decarb. Proenzime AA162205 23.9 40.8 36 27.8
Creatine kinase W50891 8 6.8 9.3 10.1
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HMG proteins
HMG(Y) AA290110 2.3 1.2 5.6 3.5
HMG2 Z46757 10.7 4.4 23.1 13.3
Enzymes
Argininosuccinate synthetase M31690 -5.6 -4.5 -6 -6.3
PAF-acetylhydrolase U34277 -5.9 -6.7 -8.6 -9.2
TransGlutaminase Tgase M55154 -1.1 -5.8 -5.3 -3.4
Aldehyde Dehydrogenase ALDH2 U07235 -1.3 -3.2 -5.3 -5.8
Rib-1 X60103 -16 -16.9 -18.5 -18-9
Dipeptidase D13139 -4 -3.8 -3.9 -5.7
Aldolase 3, isoform C W53351 -11.5 -5.5 -9.4 -7.7
Cytochrome P-450 Naphtalene Hydrox. M77497 -13 -21 -12.2 -18.2
11 β HSDH X83202 -5.5 -7.2 -7.9 -8.2
Ubiquitin-coniung.enzyme E2 W99019 5.6 8.6 3.1 7.2
Retinaldehyde-specific dehydrogenase X99273 -7.2 -6.7 -6.2 -7.2
Membrane-type matrix metalloproteinase 1 U54984 -1.8 -3.1 -6 -5.5
CAMK2  β subunit X63615 -22.6 -22.7 -31.1 -28.5
Acetylcholinesterase X56518 18.1 4.3 9.6 12.3
DNA topoisomerase II d12513 6 9.1 5.1 7.7
Ribonucleotide reductase M2 subunit m14223 4.4 7.9 5 6.6
Transcriptional factor
ID4 X75018 1.4 1.6 1.9 2.3
ID1 M31885 -4.5 -6.6 -7.5 -5.8
Zif 268 M22326 -8.3 -1.4 -14.1 -4.8
SOX-2 U31967 -8.8 -7 -10.6 -9.1
Delta-like 1 protein X80903 4.3 6.7 6 5.8
MLZ4 zinc protein AA015118 6.4 4.6 9.1 8.1
SOX-11 AF009414 7.4 9.3 11.2 10.0
Hormones
FSH-β U12932 −9.6 −5.3 −7.9 −8.8
LH-β U25145 -14 -2 -1.2 -7.1
GH Z46663 15.3 18.7 22.1 20.1
Pituitary glycoprotein hormone M22992 -1.7 -1.1 -10.6 -8.9
Thyroid-stimulating hormone M54943 -7.1 -7.7 -7.3 -7.5
Oncogenes and oncoprotein
PTTG AA711028 -1.2 -5.6 -2.4 -3.2
GARG-16 U43084 -3.6 -5.6 -10.4 -8.2
Bcl3 W62846 9.1 8.3 6.1 8.7
IFC oncogene U28495 11.2 11 10.3 15.2
Lypidic metabolism
Choline Chinase AK078101 1.3 1.9 4.4 3.3
APOBEC-1 W29206 4.2 1.6 4.6 5.1
ALBP (Adypocite lipid bunding protein) K02109 10.8 6.1 9.6 8.3
Allergic disease and infiammation
IgE receptor W41745 9.2 1.2 -1.1 -1.8
Extensin precursor AA031158 34 12.2 3.8 6.8
Mouse complement component C3 k02782 9.6 5.8 4.6 4.3
Extracellular matrix and cellular-structure
Laminin β-3 U43298 -3.8 -9.2 -14.3 -12.4
Decorin X53929 -4.6 -4.6 -5.4 -3.8
Tubulin β2 AA030364 7.1 9.3 11.3 8.9
Vsm α-ACTIN X13297 26.4 9.9 2.8 10.4
Reelin U24703 -6.2 -12 -32.7 -18.3
E-chaderin X06115 -5.4 -6.2 -5.1 -7.2
Tubulin β4 AA030364 9.9 4.3 11.3 10.1
Semaphorin H Z80941 -12.1 -8.6 -7.6 -8.9
ATP-binding cassette trasp.(ABCR) AF000149 -9.9 -10.5 -12.3 -12.5
Syntaxin 1A D45208 -5.6 -4.9 -5.6 -6.6
Folate binding protein 1 M64782 -10.1 -14.1 -16 -12.1
Growth factors
Igf2 U71085 8.6 3.5 2.8 7.2
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MIA/CD-RAP X97965 -106.6 -126.6 -121 -112
Peroxisome membrane protein (PMP22) L28835 6.5 9.6 4.1 5.9
Development
Raly L17076 -5.4 -3 -3 -4.8
Noggin U79163 7.5 8.3 10.3 7.7
NFI-β U57634 -4.5 -4.2 -7.5 -5.1
Receptor
Nicotinic Acetyl Choline rec. β subunit M14537 -13.4 -15 -24.8 -12.8
FGR receptor M33760 -5.9 -3.1 -12.5 -9.8
T-cell receptor beta chain M26417 -7.2 -5.6 -6.6 -8.6
RIP140 W85018 -6.8 -4.9 -7.1 -10.2
Serotonin 4L receptor W85018 -4.1 -5.6 -4.9 -6.9
Fc gamma receptor m14215 31.6 7.4 6 9.8
Other function
ANKT AA266783 4.4 6.1 7.5 5.5
γ -casein D10215 1 1.1 1.1 2.4
EN7 X53247 13.4 1.4 -1.7 -2.3
DMR-N9 gene Z38011 -4.3 7.3 -4.5 -5.6
Actin-2 W50919 -7 -4.4 -6.7 -9.6
Dihydropyrimidinase related protein 4 ab006715 -10 -10.6 -12.1 -13.4
Hoxc-5 U28071 -5.7 -6.6 -8.5 -11.8
Prosurvival factor
BDNF X55573 4.1 5.9 4.9 6.2
Abbreviations : FC, fold change, 1= HMGA2 induced PA1, 2= HMGA2 induced PA2, 3= HMGA2/T induced PA, 4=HMGA1
induced PA, PA= Pituitary adenoma.
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Figure 2.2.  Clustered display of
gene expression in three pituitary
adenomas developed in HMGA2-,
HMGA2/T- and HMGA1- trangenic
mice compared with normal
pituitary gland, using the MeV
program. A 4-fold difference in
express ion level  between
adenomas and normal samples
was used. The green and red
colors show downregulated and
upregulated genes, respectively.
Each gene is represented by a
single row of colored boxes; each
adenoma is represented by a
single column.
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3.2 Validation of microarray analysis
To validate the results obtained by microarray analysis we evaluated about 100
transcripts, whose expression differed of a fold change > 4 or < -4 in all the pituitary
adenomas compared to normal glands. To this aim we performed semi-quantitative
RT-PCRs in normal glands and HMGA-induced pituitary adenomas derived from
mice different from those used for the Gene Chip microarray. For all of these genes,
we confirmed the differential expression associated with the pituitary tumors. The
results of some representative RT-PCR analyses are shown in Fig. 2.3. Among these
differentially-expressed genes, there are some up-regulated (e.g. Cyclin B2 and
ANKT) and other down-regulated (e.g. Rib-1, CamK2 and Mia/Cd-rap) in pituitary
tumors with respect to the normal gland.
Figure 2.3 Validation of microarray data by semiquantitative RT-PCR. Representative RT-
PCRs on a panel of two HMGA2- one HMGA2/T-, one HMGA1-induced pituitary adenomas
and a pool of wild-type pituitary glands.
Subsequently, we also analysed by RT-PCR the expression of these genes in murine
and rat cell lines derived by pituitary adenomas of different histotype in comparison
with normal pituitary gland. Some representative results of these analyses are shown
in the Fig. 2.4. Some genes, such as Mia/Cd-rap and CamK2, as for the pituitary
adenomas of HMGA mice, are highly down-regulated in all the cell lines, whereas
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other genes, such as FKBP65 or reelin, change their expression depending on cellular
histotype.
It is known that, by interacting with different partners, the HMGA proteins are able
to enhance or suppress the effect of more “traditional” transcriptional activators and
repressors. The fact that partner proteins are critical for HMGA activity, and they
dependent on the cellular context, may account for the cell-specific regulation exerted
by the HMGA proteins.
Figure 2.4 Gene expression on a panel of seven cell lines originating by rat and mouse
pituitary adenomas of different histotype in comparison with a pool of wild-type pituitary
glands
3.3 HMGA proteins directly regulate Mia/Cd-rap and Cyclin B2 expression
Among these genes we focused our attention on the Mia/Cd-rap and Cyclin B2
genes for two main reasons: i) they were among the most changed at RNA level in all
the pituitary adenomas and different mouse and rat pituitary adenoma cell lines
analyzed; ii) they have been already associated to tumor development. In fact,
Mia/Cd-rap is upregulated in different human neoplasias such as chondrosarcoma,
melanoma, and breast cancer (Blesch et al. 1994, Chansky et al. 1998), while Cyclin
B2 is overexpressed in colorectal adenocarcinomas (Park SH et al. 2007).
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a) Mia/Cd-Rap protein is down-regulated and Cyclin B2 up-regulated in mouse
pituitary adenomas.
To further validate the microarray data obtained for the Mia/Cd-Rap and Cyclin B2
genes, we also analyzed the expression of their protein products in tissue extracts of
pituitaries and pituitary adenomas from control and transgenic mice (HMGA2,
HMGA2/T and HMGA1), respectively. As shown in Fig. 2.5, normal pituitary from
control mice show high levels of Mia/Cd-Rap protein expression, whereas it was
completely lost in pituitary adenomas from HMGA2, HMGA2/T and HMGA1
transgenic mice.
As far as concerns Cyclin B2, its expression is high in all pituitary adenomas
analyzed and it is absent in normal pituitary gland (Fig. 2.5 right).
                                        
Fig 2.5  Mia/Cd-rap and Cyclin B2 protein expression in normal pituitary from wild-type
animals and pituitary adenomas from HMGA2, HMGA2/T and HMGA1 transgenic mice.
b) HMGA Proteins bind to the Mia/Cd-rap and Cyclin B2 promoters
To investigate whether the HMGA proteins are directly involved in Mia/Cd-rap and
Cyclin B2 transcriptional regulation, we evaluated the HMGA-binding activity to the
Mia/Cd-rap- and Cyclin B2 promoters in vitro using oligonucleotides spanning from
base -1130 to -1100 of the mouse Mia/Cd-rap promoter region (Bosserhoff et al.
1997) and -229 to – 189 of the mouse Cyclin B2 promoter region, including AT-rich
sequences that are a preferential binding site for the HMGA proteins (Bolognese et al.
1999). As shown in Fig. 2.6, panel A, lanes 1-2 and 11-13, increasing amounts (5 and
20 ng) of the recombinant HMGA2 protein were capable of binding the 32P-end-
Mia/Cd-Rap Cyclin B2
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labelled double-strand oligonucleotide in Electrophoretic mobility shift assay
(EMSA). The binding specificity was demonstrated by competition experiments
showing loss of binding with the addition of 100-fold molar excess of the specific
unlabeled oligonucleotide (lane 3 and 13). We performed the same experiment with a
recombinant HMGA1 protein, and also in this case a specific binding with the
Mia/Cd-rap and Cyclin B2 promoters (Fig. 2.6, lanes 5-7, 9-10 and 14) was observed.
Subsequently, we performed binding assays with total extract from pituitary
adenomas developed in HMGA transgenic mice and normal pituitary glands from
control mice (Fig. 2.6, panel B). For both promoters, two specific complexes with a
mobility corresponding to the HMGA proteins (isoforms A1a and A1b) were present
in extracts from pituitary tumors, while they were absent in extracts from normal
glands.
To verify that HMGA proteins are able to bind to Mia/Cd-rap and Cyclin B2
promoters also in vivo, we performed experiments of chromatin immunoprecipitation
in the NIH3T3 cell line transiently transfected with either the HA-HMGA2 or HA-
HMGA1 expression plasmids. Chromatin prepared as described under Materials and
Methods was immunoprecipitated with anti-HA or normal rabbit IgG antibody. The
results, shown in Fig. 2.6, panel C, confirmed that both HMGA2 and HMGA1
proteins bind to the promoter of Mia/Cd-rap and Cyclin B2 genes also in vivo. In fact,
both promoter regions were amplified from the DNA recovered with anti-HA
antibody in HA-HMGA1- and HA-HMGA2- but not in mock-transfected cells.
Moreover, no amplification was observed in samples immunoprecipitated with
aspecific rabbit IgG.
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Fig 2.6  HMGA proteins bind Mia/Cd-rap and Cyclin B2 promoters in vitro (A e B) and in vivo (C).
C
A
B
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We demonstrated, by electrophoretic mobility shift assay and chromatin
immunoprecipitation, that both HMGA1 and HMGA2 proteins directly bind to the
promoter of these genes.
c) HMGA proteins regulate the Mia/Cd-rap and Cyclin B2 promoter activity
In order to investigate the functional effect of HMGA proteins on Mia/Cd-rap
promoter, we transiently transfected the B16F0 cell line, a murine melanoma cell line
in which Mia/Cd-rap protein is endogenously expressed, with a construct expressing
the luciferase gene under the control of the mouse Mia/Cd-rap promoter region -1396
to +1 (mMIAprom-luc) and increasing amounts of an HMGA2  (or HMGA1)
expression vector. As shown in Fig. 2.8, panel A, the overexpression of HMGA2 (or
HMGA1) resulted in a dose-dependent decreased activity of the Mia/Cd-rap
promoter. Interestingly, the HMGA1 protein showed a significantly higher inhibitory
effect on the Mia/Cd-rap promoter activity in comparison with the HMGA2 protein
(80% with 1 µg of HMGA1 versus 55% with 1 µg of HMGA2).
As far as concerns Cyclin B2 promoter, we transfected the NIH3T3 cells with the
luciferase gene under the control of the mouse cyclin B2 promoter region -1189 to-69
(Lange-zu Dohna C.et al. 2000) (Fig. 2.8 panel B). In this case, the overexpression of
HMGA2 (or HMGA1) resulted in an increased activity of the Cyclin B2 promoter,
and the HMGA1 protein showed a lower activation in comparison with the HMGA2
protein.
A
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Fig. 2.8  HMGA proteins regulate the murine Mia/Cd-rap and Cyclin B2 promoters. Luciferase
activity (fold of activation) of the Mia/Cd-rap promoter in the B16F0 murine melanoma cell line
and of Cyclin B2 promoter in the NIH3T3 cell line. Where indicated 0.5 and 1 µg of either
HMGA1 or HMGA2 expression vectors were co-transfected with the Mia-luc or with CycB2-luc
plasmids.
3.4 Mia/Cd-rap expression inhibits growth of pituitary adenoma cells
To investigate the functional role of Mia/Cd-Rap in pituitary cell growth we
performed a colony assay experiment by transfecting Mia/Cd-Rap in GH3 and GH4
rat pituitary adenoma cells. After puromicin selection, the number and growth of the
colonies obtained by transfection with the Mia expression plasmid decreased
dramatically compared to empty vector (Fig. 2.9). These results show that Mia/Cd-
Rap inhibits cell growth of rat pituitary adenoma cells, suggesting it as negative
regulator of pituitary cell proliferation.
The same experiment with the vector expressing the Cyclin B2 gene is in progress.
B
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Fig 2.9  Effect of Mia/Cd-Rap expression on pituitary adenoma cell proliferation. Colony
forming assay experiment performed in GH3 (black bars) and GH4 (gray bars) cells
transfected with a vector expressing Mia/Cd-Rap. As a control the empty vector (mock) was
used. The reported results are the mean of three experiment and error bars shows S.D.
3.5 Mia/Cd-rap and Cyclin B2 expression in human pituitary adenomas
Subsequently, we analyzed the expression of Mia/Cd-rap and Cyclin B2 in a panel
of human pituitary adenomas of different histotype by Real-time PCR (Fig. 2.10). We
found that Mia/Cd-rap expression was increased in all human pituitary adenomas
tested compared to normal gland used as a control.
As far as concerns Cyclin B2, we found that the mRNA expression level was much
higher in all human pituitary adenomas analyzed compared to normal pituitary tissue.
Interestingly, a direct correlation between HMGA1, Mia/Cd-rap and Cyclin B2
mRNA levels was observed.
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Fig. 2.10 Mia/Cd-rap, Cyclin B2 and HMGA1 expression in human pituitary tumors by real-
time PCR. NF = non functioning; GH = GH-secreting; β-FSH = β-FSH-secreting; β-LH = β-
LH-secreting; PRL = prolactin-secreting.
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4 DISCUSSION
Pituitary tumors are among the most common human neoplasms. Despite extensive
research, the pathogenesis of the majority of pituitary adenomas remains unsolved. It
is not surprising that studies into many of the common oncogenes or tumor-suppressor
genes involved in human cancer have been unrevealing when applied to these tumors.
A crucial role for the HMGA family genes in the process leading to the generation
of human pituitary adenomas was first suggested by the phenotype of transgenic mice
overexpressing a truncated or a wild-type HMGA2 gene, or wild-type HMGA1 gene,
under the transcriptional control of the strong and ubiquitous promoter of the
cytomegalovirus. Most of these mice (85% of females and 40% of males), in fact,
developed pituitary adenomas secreting prolactin and growth hormone (Fedele et al.
2002, Fedele et al. 2005).
The strong correlation between the phenotype of the HMGA2 transgenic mice and
the HMGA2 overexpression in human prolactinomas suggested that this animal model
might represent a unique tool for studying the molecular mechanisms underlying the
generation of pituitary adenomas induced by the HMGA2 overexpression. In fact
these mice allowed us to demonstrate that the mechanism of the HMGA2 induced-
pituitary adenoma development is based on the increased E2F1 activity (Fedele et al.
2006b). Since other additional mechanisms can be envisaged on the base of a minimal
residual tumoral phenotype showed by some HMGA2 transgenic mice lacking a
functional E2F1 gene (Fedele et al. 2006B), in the present study we have analysed the
gene expression profile of HMGA-pituitary adenomas in comparison with a pool of
ten normal pituitary glands in order to identify other genes involved in the process of
pituitary tumorigenesis induced by the HMGA1 and HMGA2 genes. The results of our
analysis led to the identification of 82 transcripts increased and 72 transcripts
decreased of at least 4-fold in all mice pituitary adenomas analyzed compared with
normal pituitary gland. Among these genes we focused our attention on the Mia/Cd-
rap gene and Cyclin B2 genes because they were among the most changed at RNA
level in all the pituitary adenomas.
It is noteworthy to observe that both genes have a critical role in the process of
carcinogenesis. In fact, overexpression of the human Mia/Cd-rap gene has been
associated with progression of melanocity tumors (Bosserhoff et al. 1999). The
biological function of Mia/Cd-rap in adult organism is still unclear, but evidence is
growing that it might be involved in cellular motility, metastasis, and modulation of
immune responses.
Cyclin B2 is a mitotic B-type cyclin that plays a role in entering the G2-M phase in
association with cdc2. It appears to be dispensable, in fact cyclin B2 knockout mice
develop normally but are smaller than normal mice and have reduced litter sizes,
which suggest that cyclin B2 has some growth advantage (Brandeis et al. 1998). The
overexpression of cyclin B2 contributes to the chromosomal instability observed in
cancer cells through an alteration of the spindle checkpoint (Soria et al. 2000). Very
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recently it has been demonstrated that Cyclin B2 expression is strongly associated
with colorectal adenocarcinoma (Park et al. 2007).
Cyclin B2 expression, similarly to what has been published for other neoplasias
(Park et al. 2007) is overexpressed in all pituitary adenomas analyzed compared to
normal pituitary gland.
We demonstrated, by electrophoretic mobility shift assay and chromatin
immunoprecipitation, that both HMGA1 and HMGA2 proteins directly bind to the
Cyclin B2 and Mia/Cd-rap promoters and regulate their expression in transcription
assays. We retain of particular interest this finding because, in this way, another
mechanism of HMGA-induced pituitary tumorigenesis, other than the E2F1-
dependent mechanism, can be envisaged.
Even though the expression of Mia/Cd-rap has been already associated with a
neoplastic phenotype (Blesch et al 1994, Chansky et al 1998), it has been never
described in pituitary tumorigenesis so far. Yet, there are no data that could explain us
a possible mechanism by which Mia/Cd-rap exhibits its anti-tumourigenic effect in
mouse. Moreover the exact role of this protein in this model has not been estabilished.
Interestingly, a recent study proves that HMG1, another member of the HMG
family, is an important factor in MIA regulation and melanoma progression. In fact, a
sequence-specific DNA motif in the Highly Conserved Region of the Mia/Cd-rap
promoter is recognized by HMG1 (Golob et al. 2000). Besides, recent data showed
that HMG1 is upregulated in malignant melanoma cell lines compared to Normal
Human Epidermal Melanocytes (NHEM) cell line and that it plays a pivotal role in
Mia/Cd-rap transcriptional activation (Poser et al. 2003). Consistently, the human
promoter sequence of Mia/Cd-rap contains many potential regulatory domains
including an AT-rich domain that are known DNA-binding sites for the HMGA
proteins (Bosserhoff et al. 1997).
The results of our analysis led to a role of tumor suppressor of Mia/Cd-rap in
HMGA-induced pituitary adenomas. Its expression appears inversely correlated with
the proliferative potential of pituitary adenoma cells, therefore suggesting a relevant
role for its downregulation in the generation of pituitary adenomas. Obviously, the
unsuspected tumor suppressor role of Mia/Cd-rap protein is in contrast with its
oncogenic potential that several studies, described above, have clearly estabilished.
Nevertheless, it is not the first time that a gene has been shown to have both
oncogenic and antioncogenic properties (Evan et al. 1995). In the case of Mia/Cd-rap
this effect could be explained by a hypothetic mechanism of action of Mia/Cd-rap,
which could regulate the expression of several genes by interacting with diverse
partners. Because their protein(s) partner might change depending on the cell-type,
Mia/Cd-rap-dependent gene regulation may also depend on the cellular context,
which could account for the dual role of this protein in pituitary tumorigenesis.
In further studies, potential interactor(s) of Mia/Cd-rap protein, as well as
downstream signaling pathways, in pituitary adenomas, have to be determined.
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Yet, further investigation is required to shed light on the functional relevance of
Mia/Cd-rap and Cyclin B2 gene regulation in the generation of pituitary adenomas.
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5 CONCLUSIONS
• We have identified new genes regulated by HMGA proteins in HMGA-induced
pituitary adenomas.
• HMGA proteins are implicated in many different pathways since we have found
that the genes regulated by HMGA proteins belong to diverse families and
have very diverse roles.
• HMGA exert positive and negative gene regulation since we have found some of
the genes up-regulated and some down-regulated by HMGA proteins.
• We have demonstrated that the regulation is direct in some cases, such as
Mia/Cd-rap and Cyclin B2.
• The expression of Mia/Cd-rap appears inversely correlated with the growth
potential of rat pituitary adenoma cells mouse pituitary adenomas.
• The expression of Mia/Cd-rap and Cyclin B2 is increased in human pituitary
adenomas compared to normal tissue and is directly correlated with the
expression of HMGA1.
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